Entry id

1_bfif1ne4

Invasive disease-free survival is the most common endpoint being looked at now in adjuvant clinical trials because it gives us the information we most care about and patients most care about: recurrence of breast cancer, whether that be locally, regionally, distant or, of course, death from breast cancer as well as the development of a new second primary. Essentially, we want to prevent breast cancer recurrence. Women do not want to see it again, and that is why it is a very, very clinically meaningful endpoint for us.